研究单位：[1]Beijing Tongren Hospital,CMU,Beijing,China[2]Yingu Pharmaceutical Co., Ltd[3]Beijing friendship hospital, CMU,Beijing,China[4]Beijing Shijitan Hospital,CMU,Beijing,China[5]The third affliation hospital of Sun YAT-SEN university,Guangzhou,Guangdong,China[6]Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology,Wuhan,Hubei,China[7]Jiangsu Province hospital,Nanjing,Jiangsu,China
450 subjects with moderate-severe persistent allergic rhinitis will be enrolled in the trial and divided into three groups for different treatments. Group A：Subjects with Bencycloquidium Bromide Nasal Spray, Group B：Subjects with Mometasone Furoate Aqueous Nasal Spray, Group C：Subjects with Bencycloquidium Bromide Nasal Spray in combination with Mometasone Furoate Aqueous Nasal Spray.The main purpose of the trial is to evaluate the efficacy of Bencycloquidium Bromide Nasal Spray alone or in combination with Mometasone Furoate Aqueous Nasal Spray in the treatment of moderate-severe persistent allergic rhinitis and rhinorrhea.
